Literature DB >> 17114458

Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia.

Rozen Le Panse1, Géraldine Cizeron-Clairac, Jacky Bismuth, Sonia Berrih-Aknin.   

Abstract

Myasthenia gravis (MG) is an autoimmune disease mainly caused by antiacetylcholine receptor autoantibodies (seropositive (SP) disease) or by Abs against unknown autoantigenic target(s) (seronegative (SN) disease). Thymectomy is usually beneficial although thymic hyperplasia with ectopic germinal centers is mainly observed in SP MG. To understand the role of thymus in the disease process, we compared the thymic transcriptome of non-MG adults to those of SP patients with a low or high degree of hyperplasia or SN patients. Surprisingly, an overexpression of MHC class II, Ig, and B cell marker genes is observed in SP but also SN MG patients. Moreover, we demonstrate an overexpression of CXCL13 in all MG thymuses leading probably to the generalized B cell infiltration. However, we find different chemotactic properties for MG subgroups and, especially, a specific overexpression of CCL21 in hyperplastic thymuses triggering most likely ectopic germinal center development. Besides, SN patients present a peculiar signature with an abnormal expression of genes involved in muscle development and synaptic transmission, but also genes implicated in host response, suggesting that viral infection might be related to SN MG. Altogether, these results underline differential pathogenic mechanisms in the thymus of SP and SN MG and propose new research areas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17114458      PMCID: PMC1892191          DOI: 10.4049/jimmunol.177.11.7868

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

1.  Genomic anatomy of a premier major histocompatibility complex paralogous region on chromosome 1q21-q22.

Authors:  T Shiina; A Ando; Y Suto; F Kasai; A Shigenari; N Takishima; E Kikkawa; K Iwata; Y Kuwano; Y Kitamura; Y Matsuzawa; K Sano; M Nogami; H Kawata; S Li; Y Fukuzumi; M Yamazaki; H Tashiro; G Tamiya; A Kohda; K Okumura; T Ikemura; E Soeda; N Mizuki; M Kimura; S Bahram; H Inoko
Journal:  Genome Res       Date:  2001-05       Impact factor: 9.043

2.  DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming.

Authors:  A B Bakker; R M Hoek; A Cerwenka; B Blom; L Lucian; T McNeil; R Murray; L H Phillips; J D Sedgwick; L L Lanier
Journal:  Immunity       Date:  2000-09       Impact factor: 31.745

3.  Chemokines define distinct microenvironments in the developing thymus.

Authors:  C C Bleul; T Boehm
Journal:  Eur J Immunol       Date:  2000-12       Impact factor: 5.532

4.  Expression of metabotropic glutamate receptors in murine thymocytes and thymic stromal cells.

Authors:  M Storto; U de Grazia; G Battaglia; M P Felli; M Maroder; A Gulino; G Ragona; F Nicoletti; I Screpanti; L Frati; A Calogero
Journal:  J Neuroimmunol       Date:  2000-09-22       Impact factor: 3.478

5.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

6.  Transcription repression of human hepatitis B virus genes by negative regulatory element-binding protein/SON.

Authors:  C T Sun; W Y Lo; I H Wang; Y H Lo; S R Shiou; C K Lai; L P Ting
Journal:  J Biol Chem       Date:  2001-04-16       Impact factor: 5.157

7.  Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis.

Authors:  G P Sims; H Shiono; N Willcox; D I Stott
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

8.  BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis.

Authors:  S A Luther; T Lopez; W Bai; D Hanahan; J G Cyster
Journal:  Immunity       Date:  2000-05       Impact factor: 31.745

Review 9.  Pathogenic autoantibodies to neuronal proteins in neurological disorders.

Authors:  A Vincent; O Lily; J Palace
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

10.  Lymphoid neogenesis in rheumatoid synovitis.

Authors:  S Takemura; A Braun; C Crowson; P J Kurtin; R H Cofield; W M O'Fallon; J J Goronzy; C M Weyand
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

View more
  18 in total

1.  Granzyme B: evidence for a role in the origin of myasthenia gravis.

Authors:  L Casciola-Rosen; A Miagkov; K Nagaraju; F Askin; L Jacobson; A Rosen; D B Drachman
Journal:  J Neuroimmunol       Date:  2008-08-03       Impact factor: 3.478

Review 2.  Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review.

Authors:  Frédérique Truffault; Vincent de Montpreville; Bruno Eymard; Tarek Sharshar; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

3.  Intrathymic Tfh/B Cells Interaction Leads to Ectopic GCs Formation and Anti-AChR Antibody Production: Central Role in Triggering MG Occurrence.

Authors:  Xiaoyan Zhang; Shasha Liu; Ting Chang; Jiang Xu; Chunmei Zhang; Feng Tian; Yuanjie Sun; Chaojun Song; Wei Yi; Hong Lin; Zhuyi Li; Kun Yang
Journal:  Mol Neurobiol       Date:  2014-11-19       Impact factor: 5.590

Review 4.  Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.

Authors:  Marieke Robinet; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

5.  Inflammation and epstein-barr virus infection are common features of myasthenia gravis thymus: possible roles in pathogenesis.

Authors:  Paola Cavalcante; Lorenzo Maggi; Lara Colleoni; Rosa Caldara; Teresio Motta; Carmelo Giardina; Carlo Antozzi; Sonia Berrih-Aknin; Pia Bernasconi; Renato Mantegazza
Journal:  Autoimmune Dis       Date:  2011-09-26

6.  Detecting key genes regulated by miRNAs in dysfunctional crosstalk pathway of myasthenia gravis.

Authors:  Yuze Cao; Jianjian Wang; Huixue Zhang; Qinghua Tian; Lixia Chen; Shangwei Ning; Peifang Liu; Xuesong Sun; Xiaoyu Lu; Chang Song; Shuai Zhang; Bo Xiao; Lihua Wang
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

7.  IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis.

Authors:  Marie Maurer; Sylvain Bougoin; Tali Feferman; Mélinée Frenkian; Jacky Bismuth; Vincent Mouly; Geraldine Clairac; Socrates Tzartos; Elie Fadel; Bruno Eymard; Sara Fuchs; Miriam C Souroujon; Sonia Berrih-Aknin
Journal:  Acta Neuropathol Commun       Date:  2015-01-15       Impact factor: 7.801

8.  Blood Transcriptome Profiling in Myasthenia Gravis Patients to Assess Disease Activity: A Pilot RNA-seq Study.

Authors:  Kee Hong Park; Junghee Jung; Jung-Hee Lee; Yoon-Ho Hong
Journal:  Exp Neurobiol       Date:  2016-02-22       Impact factor: 3.261

9.  Prioritizing genes of potential relevance to diseases affected by sex hormones: an example of myasthenia gravis.

Authors:  Mandeep Kaur; Sebastian Schmeier; Cameron R MacPherson; Oliver Hofmann; Winston A Hide; Stephen Taylor; Nick Willcox; Vladimir B Bajic
Journal:  BMC Genomics       Date:  2008-10-13       Impact factor: 3.969

10.  Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis.

Authors:  Julia Miriam Weiss; Marieke Robinet; Revital Aricha; Perrine Cufi; Bérengère Villeret; Frida Lantner; Idit Shachar; Sara Fuchs; Miriam C Souroujon; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Oncotarget       Date:  2016-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.